FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - November 13, 2024 66 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved the VENTANA CLDN18 (43-14A) RxDx Assay as a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab to Unresectable or Advanced HCC ESMO Sarcoma and Rare Cancers Congress 2025, Lugano, Switzerland, 20-22 March New on NCI’s Websites for March 2025 MOST POPULAR New drug available for rare thyroid cancer on NHS in England October 1, 2021 News digest – skin cancer deaths, Public Health England plans and... August 22, 2020 Can I Have a Nonviolent Relationship with Cancer? (Part 1) November 15, 2021 Mississippi Teen Uses Make-A-Wish Grant To Feed Homeless In His Community November 13, 2021 Load more HOT NEWS Five Questions With…Stephen. The Gift of Time Embracing Lung Cancer Survivorship Association of BRCA1 and BRCA2 Pathogenic Variants with Increased Risk of...
